Press coverage about Fluidigm (NASDAQ:FLDM) has trended positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fluidigm earned a news impact score of 0.27 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 44.8576539507392 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Fluidigm (NASDAQ:FLDM) traded up $0.01 during mid-day trading on Wednesday, reaching $6.86. The company’s stock had a trading volume of 22,473 shares, compared to its average volume of 217,686. The company has a debt-to-equity ratio of 6.31, a quick ratio of 2.38 and a current ratio of 2.83. The company has a market capitalization of $264.31, a P/E ratio of -3.60 and a beta of 2.97. Fluidigm has a 12-month low of $2.52 and a 12-month high of $8.38.

How to Become a New Pot Stock Millionaire

Fluidigm (NASDAQ:FLDM) last posted its quarterly earnings results on Thursday, February 8th. The medical research company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02). The company had revenue of $27.75 million during the quarter, compared to the consensus estimate of $27.14 million. Fluidigm had a negative net margin of 59.38% and a negative return on equity of 118.56%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.32) earnings per share. equities analysts forecast that Fluidigm will post -0.93 EPS for the current fiscal year.

A number of research analysts recently issued reports on the company. Piper Jaffray Companies reiterated a “hold” rating and set a $6.10 price objective on shares of Fluidigm in a report on Thursday, February 8th. ValuEngine downgraded Fluidigm from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, BidaskClub upgraded Fluidigm from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 13th.

In related news, insider Levin Capital Strategies, L.P. purchased 40,000 shares of the firm’s stock in a transaction on Thursday, March 8th. The stock was purchased at an average cost of $6.48 per share, for a total transaction of $259,200.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders acquired 750,191 shares of company stock valued at $4,656,189. Corporate insiders own 4.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Fluidigm (FLDM) Earning Positive News Coverage, Study Shows” was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/03/14/fluidigm-fldm-earning-positive-news-coverage-study-shows.html.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

Insider Buying and Selling by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.